

## Up-regulation of nitric oxide synthases by erythropoietin alone or in conjunction with ischemic preconditioning in ischemia reperfusion injury of rat kidneys

Mohammed Elshiekh<sup>1</sup>, Mehri Kadkhodae<sup>2</sup>, Behjat Seifi<sup>2</sup>, Mina Ranjbaran<sup>2</sup> and Hassan Askari<sup>2</sup>

<sup>1</sup> *Department of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, International campus, Tehran, Iran*

<sup>2</sup> *Department of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran*

**Abstract.** The effects of erythropoietin (EPO) alone or in conjunction with ischemic preconditioning (IPC) on nitric oxide synthase as well as comparing their effects on oxidative stress and proinflammatory cytokines are studied. Rats underwent bilateral renal ischemia of 50 min followed by 24 h reperfusion. They were administered EPO (5000 iu/kg i.p.) and/or subjected to IPC and sacrificed after 24 h, then plasma and tissue samples were obtained. Treatment of either EPO or IPC and their combination attenuates oxidative stress, decreases histological damages, inhibits proinflammatory response, and up-regulates iNOS and eNOS gene expression compared to IR group. In addition, EPO+IPC and EPO treatment produced significant up-regulation in iNOS gene expression compared to IPC group. In IPC and EPO+IPC groups, more powerful effect on up-regulation of eNOS gene expression was shown compared to EPO group. Our findings suggest that treatment with EPO or IPC and their combination improve renal function and preserve tubular damage induced by IR injury. These advantageous effects were closely related to reducing oxidative stress, suppressing proinflammatory response and enhancing generation of NO. IPC was more powerful in enhancement of eNOS gene expression compared to EPO that was more effective in increasing of iNOS gene expression.

**Key words:** Ischemia reperfusion — Oxidative stress — Proinflammatory response — iNOS — eNOS

### Introduction

Renal ischemia-reperfusion (IR) injury, an inflammatory pathophysiological process, leads to acute kidney failure, delayed graft function, and early mortality in patients subjected to kidney transplantation (Kosieradzki and Rowinski 2008). Several factors have crucial roles in the pathophysiology of IR injury, such as vascular endothelium, leukocytes, reactive oxygen species and adhesion molecules as well as inflammatory mediators (Elahi et al. 2009). Overproduction of ROS results in an increase in lipid peroxidation (MDA) by devastated unsaturated fatty acids in the cell membrane producing a decrease in endogenous antioxidants enzymes such as SOD (Wang et al. 2013).

Nitric oxide (NO) as a biological mediator plays an important role in a variety of biological processes and is a fundamental component in the fields of biochemistry, physiology, immunology and neuroscience (Omer et al. 2012). NO is known as an essential mediator of physiological and pathological processes of renal IR injury (Lopez-Marti et al. 2003). NO is produced from L-arginine by the enzyme nitric oxide synthase (NOS), which exists in three forms. Two are constitutive, neuronal nitric oxide synthase (nNOS, also known as NOS I) and endothelial nitric oxide synthase (eNOS, also known as NOS III) and one is inducible (iNOS, also known as NOS II, Ignarro 2000). Recent studies suggest the presence of a potentially new isoform of NOS in mitochondria (mtNOS) which was characterized as a constitutive NOS isoform (Giulivi et al. 1998; Ghafourifar et al. 1999). NO regulates neutrophil recruitment by suppressing the expression of adhesion molecules in the vascular endothelium producing increased blood flow to ischemic regions (Laroux et al. 2001).

Correspondence to: Mehri Kadkhodae, Department of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran  
E-mail: kadkhodm@tums.ac.ir

Erythropoietin (EPO) is a complex molecule, which regulates red blood cell production in the bone marrow. Recombinant human EPO (rHuEPO) is commercially available and is widely used for the treatment of anemia (Boissel and Cerami 1993). EPO has been shown to protect different organs including brain, heart, and kidney against IR injury (Brines et al. 2008). EPO mediates cytoprotective effects by regulating a variety of signal pathways, which comprise mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt (Li et al. 2013; Kwon et al. 2014). It has been documented that PI3K/Akt signaling pathway activation exerts protective effects on IR, as activated Akt increases the expression of eNOS and the generation of NO in endothelial cells (Yao et al. 2013). Nevertheless, the cytoprotective mechanisms underlying the effects of EPO on renal IR injury remain to be fully elucidated.

Ischemic preconditioning (IPC), known as brief sporadic episodes of ischemia alternating with reperfusion, increases the tolerance of the ischemic kidneys against sustained IR injury (Hausenloy and Yellon 2009). Despite intensive investigations, the mechanisms mediating this protective effect are still unclear. However, it has been documented that the benefits of IPC may be mediated by the synthesis of vasoactive mediators, such as nitric oxide (Park et al. 2003). In previous study, we reported the ameliorative effect of EPO and IPC individually on renal IR injury in rats. In that study both treatments have been able to ameliorate renal dysfunction and oxidative stress in kidney tissues (Elshiekh et al. 2015). In the current study, we investigated the effects of EPO alone or in conjunction with IPC on different nitric oxide synthases gene expression as well as comparing their effects on oxidative stress and proinflammatory cytokines.

## Materials and Methods

### Animals

Male Wistar albino weighing 230–300 g were provided by Tehran University of Medical Sciences. Rats were kept in ordinary group cages in a temperature-controlled ( $21 \pm 1^\circ\text{C}$ ) with a 12/12 h light/dark cycle. They were fed with a standard rat chow and allowed to drink water *ad libitum*. The study protocol was reviewed and approved by the Animal Care and Use Committee of the Tehran University of Medical Sciences, School of Medicine.

### Surgical procedures

Rats were anesthetized by an intraperitoneal administration of ketamine (50 mg/kg) and xylazine (10 mg/kg) and placed on a heating pad in order to maintain their body temperature at  $37 \pm 1^\circ\text{C}$ . A tail-cuff was connected to

a pulse transducer device (MLT125/R; AD Instruments, Castle Hill, NSW, Australia) for the measurement of systolic blood pressure and heart rate. The transducer was linked to a PowerLab/4SP data-acquisition system (Chart, version 5; AD Instruments). Based on this technique, rats with blood pressure below 60 mmHg were excluded from the study. A midline laparotomy was performed, in which the abdominal cavity was fully exposed. Bilateral renal pedicles were isolated carefully and blood supply to both kidneys was interrupted by clamping renal vascular pedicles with a non-crushing microvascular clamp. Reperfusion was performed after 50 min ischemia to allow return of blood flow to the kidneys for 24 hours. The edges of the abdominal incision were sutured in two layers.

IPC was performed by three cycles of alternating 3 minutes of bilateral renal pedicles ischemia and 3 minutes reperfusion. The occlusion was achieved by non-crushing microvascular clamp.

### Study design

Animals were allocated randomly into five groups:

IR group ( $n = 6$ ): rats were underwent 50 min ischemia followed by 24 h reperfusion,

Sham group ( $n = 6$ ): rats were underwent same surgical procedures without induction of bilateral IR,

EPO group ( $n = 6$ ): rats were administered EPO 5000 iu/kg i.p. 30 min before IR,

IPC group ( $n = 6$ ): similar to IR group but, 3 cycles of 3 min ischemia followed by 3 min reperfusion (IPC method) were performed before induction of IR,

EPO+IPC group ( $n = 6$ ): similar to IR group but EPO 5000 iu/kg was administered (30 min before IR) plus IPC was performed before induction of IR.

At the end of the surgery, rats were kept in individual metabolic cages for urine collection over a period of 24 h. After 24 h reperfusion, they were anesthetized by a mixture of ketamine (50 mg/kg) and xylazine (10 mg/kg) and blood samples were collected from the *inferior vena cava*. Rats were sacrificed and their kidneys were harvested before being washed and dissected in cold normal saline. The kidneys were immediately harvested, either fixed in 10% formalin for histology or snaps frozen in liquid nitrogen and stored at  $-70^\circ\text{C}$  for oxidative stress and RT-PCR analysis. EPO was partly a gift from Pooyesh Darou Company.

### Measurement of biochemical parameters

Urine samples were gathered throughout reperfusion period, and the volume produced was recorded. Urine concentrations of creatinine and  $\text{Na}^+$  were measured at the end of reperfusion period and were utilized in conjunction with plasma concentrations to estimate creatinine clearance

(CCr) and fractional excretion of  $\text{Na}^+$  (FENa) using standard formulae. These were used as indicators of glomerular and tubular function respectively.

#### Renal oxidative stress assessments

Renal oxidative stress was evaluated by measuring renal malondialdehyde (MDA, an index for lipid peroxidation) and superoxide dismutase (SOD, an endogenous antioxidant enzyme).

#### Estimation of inflammatory biomarkers

Tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and interleukin 6 (IL-6) were determined in the plasma using a rat TNF- $\alpha$  and IL-6 ELISA kit (R&D Systems, Inc, USA) and expressed as pg/ml wet tissue.

#### Histopathological examination

A part of each kidney was fixed in 10% formalin, then routinely treated and embedded in paraffin. Thin slices (5  $\mu\text{m}$ ) were cut and stained with hematoxylin and eosin (H&E). Slides were then assessed and images were captured utilizing a digital camera comprised in a light microscope.

#### Real Time PCR

Total RNA from kidney tissue samples was prepared with RLT reagent according to the manufacturer's instructions (RNeasy Mini Kit; Qiagen). RNA quality and concentration were determined using the Nanodrop 1000 (Thermo-Scientific, USA). Four micrograms of total RNA was reverse-transcribed into cDNA with the use of the PrimeScript RT Master Mix (Takara, Japan) as instructed. Gene amplification was achieved in 0.2  $\mu\text{l}$  volume microtube in ABI7500 real-time PCR. The reaction mixture comprised 4  $\mu\text{l}$  of diluted cDNA, 5 pM of each primer, 10  $\mu\text{l}$  of 2X SYBR green master mixes in a total volume of 20  $\mu\text{l}$ .

The PCR protocol was accomplished as follows; initial step of 95°C for 15 min, amplification step of 40 cycles at

95°C for 15 s followed by 1 min at 58°C. This program was followed by analysis of melting curve that was performed with linear heating from 60–90°C.

Under similar conditions, the PCR assay was performed with HPRT-1 as a house keeping gene using specific primers (Table 1) and considered as internal control.

#### Statistical analysis

The software of SPSS version 13 (SPSS Inc, IL, USA) was used for statistical analysis. All values depicted in the text and figures were showed as the mean  $\pm$  SEM. Data were analyzed using one-way ANOVA followed by post hoc Tukey's test;  $p < 0.05$  was considered significant.

## Results


#### Renal function and histology

Compared to the sham group, rats that subjected to IR showed a significant decrease in CCr and a significant increase in FENa ( $p < 0.05$ ). Pretreatment with EPO and IPC produced a significant protective effect against the IR-induced deterioration of renal function ( $p < 0.05$ ). However, EPO treatment along with IPC showed a better improvement, although not statistically significant, in the markers of renal function compared to the other treated groups (Figure 1).

Sham group had normal histology by light microscopy. In the IR group, the sections showed severe damage including frequent cast formation in the tubules. Cellular disintegration was seen especially in the mid-cortical and cortico-medullary tubules. These features were compatible with necrotic changes. In the tissues of IPC group, less tubular damage was seen. Although, some tubular debris were also present. The same histological characteristics applied to EPO group in which moderate improvement was seen comparing to IR group. However, these sections were not different from IPC tissues. In the EPO+IPC group, there was more improvement comparing to the other two treatment groups.

**Table 1.** Primers used for Real-Time PCR analysis

Gene	Specific primers	
iNOS	Sense Strand Sequence	TCGCTGGTTTGAAACTTCTCAG
	Anti-Sense Strand Sequence	CTCCGTGGGGCTTGATAGTTGA
eNOS	Sense Strand Sequence	GGCTGAGTACCCAAGCTGAG
	Anti-Sense Strand Sequence	ATTGTGGCTCGGGTGGATTT
HPRT-1	Sense Strand Sequence	CTCCTCAGACCGCTTTTCCC
	Anti-Sense Strand Sequence	AGCAAGTCTTTTCAGTCTGTGCC



**Figure 1.** Effect of erythropoietin (EPO) and/or ischemic preconditioning (IPC) on renal function markers: creatinine clearance (CCr; **A**) and fractional excretion of sodium (FENa; **B**). Data represent mean  $\pm$  SEM ( $n = 6$ ); \*  $p < 0.05$  vs. Sham group, #  $p < 0.05$  vs. IR group. IR group, rats were subjected to renal ischemia followed by reperfusion; EPO group, rats treated with EPO before IR procedure; IPC group, rats were subjected to ischemic preconditioning before IR procedure; EPO+IPC group, rats treated with EPO and IPC before IR procedure.


No obvious necrosis was detected and less luminal debris was observed. (Figure 2).

#### Renal oxidative stress

Rats underwent renal IR showed a significant raise in renal MDA content, and a significant decrease in renal SOD activity ( $p < 0.05$ ). Pretreatment with EPO and/or IPC revealed a significant reduction in renal MDA content and a significant increase in renal SOD activity compared to IR group ( $p < 0.05$ ). (Figure 3A and B).

#### TNF- $\alpha$ and IL-6

Rats underwent renal IR showed a substantial increase in plasma levels of TNF- $\alpha$  and IL-6, compared to sham group ( $p < 0.05$ ). All three treatment groups showed significant decreases in plasma levels of TNF- $\alpha$  and IL-6, compared to IR group ( $p < 0.05$ ). However, in the combination group the reduction in plasma TNF- $\alpha$  was more prominent so its level was not significantly different from the sham group. (Figure 3C and D).



**Figure 2.** Effect of erythropoietin (EPO) and/or ischemic preconditioning (IPC) on renal histological changes induced by renal ischemia reperfusion in EPO group (A), IPC group (B) and EPO+IPC group (C). Kidney sections were stained with hematoxylin and eosin (H&E, scale bar: 100  $\mu$ m, magnification:  $\times 400$ ).

*iNOS and eNOS expression*


Real time PCR showed a significant increase in iNOS gene expression in all studied groups (IR, EPO, IPC and EPO+IPC) compared to sham group ( $p < 0.05$ ). There is no difference in eNOS gene expression between IR and sham groups. Furthermore, EPO pretreatment or IPC and their combination showed a significant increase in iNOS and eNOS gene expression compared to IR group ( $p < 0.05$ ). EPO+IPC and EPO groups showed significant increases in iNOS gene expression compared to IPC group ( $p < 0.05$ ). In addition, EPO+IPC and IPC groups showed a significant increase in the eNOS gene expression compared to EPO group ( $p < 0.05$ ) (Figure 4A and B).

**Discussion**


In the present study, we have investigated the effects of EPO alone or in conjunction with IPC on NOS gene expression as well as comparing their effect on oxidative stress and proinflammatory cytokines. We demonstrated that pretreat-

ment with either EPO or IPC was equipotent in ameliorating renal damage and dysfunction. In addition, we demonstrated that both of the treatments and their combination could effectively attenuate renal injury in rat kidney IR model. The protective effects of EPO and IPC were associated with enhanced up-regulation of iNOS and eNOS gene expression.

NO is suggested to have crucial role in normal and pathophysiological process of renal IR (Lopez et al. 2003). It down-regulates inflammatory reactions, which are the main contributors to IR injury (Laroux et al. 2001). Furthermore, NO regulates neutrophil recruitment by suppressing the expression of adhesion molecules in the vascular endothelium causing increased blood flow to the ischemic regions. NO generation is mediated by the activities of NOS enzymes, whose expression is, in turn, altered by signaling pathways involved in inflammation, such as NF- $\kappa$ B and MAPK (Hickey et al. 2001; Laroux et al. 2001). Vinas and co-workers documented that NO may have a protective effect due to its anti-apoptotic action to decrease leukocyte-endothelial interactions. NO formation can result in vasodilatation and inhibition of platelet plug formation, as well as reduction of the inflammatory response (Vinas et al. 2006). Thus, protec-



**Figure 3.** Effect of EPO and/or IPC on renal malondialdehyde (MDA) content (A), renal superoxide dismutase (SOD) activity (B), tumor necrosis factor (TNF- $\alpha$ ) (C) and plasma interleukin 6 (IL-6) (D). Data represent mean  $\pm$  SEM ( $n = 6$ ); \*  $p < 0.05$  vs. Sham group, #  $p < 0.05$  vs. IR group. (For abbreviations, see Figure 1).



**Figure 4.** Effect of EPO and/or IPC on iNOS (A) and eNOS (B) gene expression. Data represent mean  $\pm$  SEM ( $n = 6$ ); \*  $p < 0.05$  vs. Sham group, #  $p < 0.05$  vs. IR group, \$  $p < 0.05$  vs. treatment groups (EPO, IPC, EPO+IPC). (For abbreviations, see Figure 1).

tive effects of NO may depend on its concentration, site of release and duration of action (Goligorsky et al. 2004).

In this study, there was a significant increase in iNOS gene expression in IR group compared to sham animals and this enhancement was even higher in the treatment groups. Study by Torras et al. (2002) documented that NOS-generated NO suppressed IR-induced renal damage and the beneficial effect of preconditioning is related to the local production of NO. It seems that the defense system of the body has started to protect the kidney from IR injury by enhancement of NO production through inducing NOS enzyme activity and this protective effect has been reinforced by treatments.

The effect of IPC alone or in combination with EPO was more powerful in enhancement of eNOS gene expression than EPO alone. Furthermore, the present study demonstrated more enhancement in the gene expression of iNOS by EPO treatment and combination than IPC alone. There is evidence that EPO stimulates the phosphorylation of serine residues on eNOS, resulting in its activation (Mastromarino et al. 2011). EPO mediates cytoprotective effects by regulating a variety of signal pathways, which comprise MAPKs and PI3K/Akt (Li et al. 2013; Kwon et al. 2014). It has been documented that PI3K/Akt signaling pathway activation exerts protective effects on IR, as activated Akt increases the expression of eNOS and the generation of NO in endothelial cells (Yao et al. 2013). Recently, Ge et al. (2015) demonstrated that in rats, IPC contributes to the early restoration of renal affective blood flow (RABF), probably through eNOS and iNOS-mediated NO production thereby alleviating IR-induced renal dysfunction and histological damage. IPC, known as brief sporadic episodes of ischemia alternating with reperfusion, increases the tolerance of the ischemic kidneys against sustained IR injury (Hausenloy et al. 2009). Despite intensive investigations, the mechanisms responsible for this protective effect is still unclear. However, it has been documented that the benefits of IPC may be mediated by the synthesis of vasoactive mediators, such as NO (Park et al. 2003). In this study, we demonstrated that IPC, either alone or in combination with EPO, increased iNOS and eNOS gene

expression comparing with IR group. IPC was more powerful in enhancement of eNOS gene expression compared to EPO. Barrier et al. (2005) reported that IPC stimulates the production of NO through up-regulation of iNOS gene expression. In addition, activation of eNOS is beneficial as the enhanced production of NO results in local vasodilation, suppresses adhesion of platelets and neutrophils, and regulates angiogenesis (Tyml 2011). Factors that release NO or reinforce the generation of endogenous NO may attenuate excessive intra-renal vasoconstriction and reduce renal dysfunction (Kwon et al. 2009). Thus, up-regulation of iNOS and eNOS mediated by EPO and IPC may contribute to the beneficial effects of EPO and IPC which was reported here.

Renal ischemia reperfusion injury resulted in an increased generation of proinflammatory cytokines such as TNF- $\alpha$  and IL-6 (Rezende-Neto et al. 2002). TNF- $\alpha$  mediates activation of endothelium to express adhesion molecules and additional proinflammatory molecules. These mediators arouse the infiltration of cells into tubulointerstitium to encourage further inflammation and tissue deterioration (Ysebaert et al. 2000). In the present study, plasma TNF- $\alpha$  and IL-6 were noted to be markedly increased in the animals subjected to IR injury compared to sham rats. These results further substantiate that IR-associated proinflammatory response may contribute to the pathogenesis of renal IR injury. Treatment with EPO and/or IPC significantly attenuated IR-induced increase in plasma TNF- $\alpha$  and IL-6 level. Thus it may be suggested that the reno-protective effects of EPO and IPC against renal damage and dysfunction might be associated with their actions in reducing circulating proinflammatory cytokines. These findings are in agreement with Ates et al. (2005) which documented that EPO treatment suppresses renal inflammation during IR damage by reducing proinflammatory cytokines, TNF- $\alpha$  and IL-6 activation. Therefore, inhibition of inflammatory response may be the potential mechanisms of reno-protective effects of EPO and IPC against renal IR injury.

In the current study, we demonstrated that treatment with EPO or IPC and their combination produced a substantial improve in tubular and glomerular function as pointed by

a marked increase in CCr, and substantial decrease in FENa and changes in histologic features compared to the IR group. Our findings of a protective effect of EPO pretreatment in IR injury are in good agreement with previous study (Zhang et al. 2015) demonstrating the beneficial effect of EPO pretreatment in improving renal function and histology. Tsutsui et al. (2013) reported that IPC induced substantial improvement in renal function markers and histological features. In the present study, the results from EPO+IPC group, namely cast formation, cellular disintegration in mid-cortical and corticomedullary tubules, tubular damage and necrosis were significantly less compared to rats treated with EPO or IPC alone.

Regarding oxidative stress, our present study revealed that 50 min ischemia followed by 24 h reperfusion produced a marked decrease in SOD activity. These findings are in agreement with previous reports demonstrating that IR induces oxidative stress as evidenced by decreasing SOD activity and increasing MDA content (Sheridan and Bonventre 2001). In the present study we demonstrated that treatment with EPO or IPC and their combination markedly ameliorated oxidative stress by increasing SOD activity and consequently by decreasing MDA content. In consistent with our study, administration of EPO along with sodium selenite decreased oxidative stress and activated PI3K/NO signaling pathway (Liu et al. 2015) in a rat ischemia-reperfusion induced renal injury model. Shokeir et al. (2015) documented that combination of IPC and sulforaphane offered more improvements in the antioxidant enzymes and inflammatory state, but not the apoptotic markers.

In conclusion, our findings suggested that treatment with EPO and/or IPC improve renal function and decrease tubular damage induced by IR. These advantageous effects were closely related to reducing oxidative stress, suppressing proinflammatory response and enhancing generation of NO *via* up-regulation of iNOS and eNOS gene expression. In addition, our findings demonstrate that up-regulation of iNOS and eNOS are essential for EPO- and IPC-mediated amelioration of renal function in IR injury.

**Acknowledgement.** This work was supported by a grant from the International Campus of Tehran University of Medical Sciences (No 27596).

**Conflict of interest.** On behalf of all authors, the corresponding author states that there is no conflict of interest.

## References

- Ates E., Yalcin A. U., Yilmaz S., Koken T., Tokyol C. (2005): Protective effect of erythropoietin on renal ischemia and reperfusion injury. *ANZ J. Surg.* **75**, 1100–1105  
<https://doi.org/10.1111/j.1445-2197.2005.03612.x>
- Barrier A., Olaya N., Chiappini F., Roser F., Scatton O., Artus C., Franc B., Dudoit S., Flahault A., Debuire B., Azoulay D., Lemoine A. (2005): Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL-1Ra, iNOS, and Bcl-2 in a human model of liver ischemia-reperfusion. *FASEB J.* **19**, 1617–1626  
<https://doi.org/10.1096/fj.04-3445com>
- Boissel J. P., Lee W. R., Presnell S. R., Cohen F. E., Bunn H. F. (1993): Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. *J. Biol. Chem.* **268**, 15983–15993
- Brines M., Cerami A. (2008): Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. *J. Int. Med.* **264**, 405–432  
<https://doi.org/10.1111/j.1365-2796.2008.02024.x>
- Elahi M. M., Kong Y. X., Matata B. M. (2009): Oxidative stress as a mediator of cardiovascular disease. *Oxid. Med. Cell Longev.* **2**, 259–269  
<https://doi.org/10.4161/oxim.2.5.9441>
- Elshiekh M., Kadkhodae M., Seifi B., Ranjbaran M., Ahghari P. (2015): Ameliorative effect of recombinant human erythropoietin and ischemic preconditioning on renal ischemia reperfusion injury in rats. *Nephro. Urol. Mon.* **7**, e31152  
<https://doi.org/10.5812/numonthly.31152>
- Ge Y. Z., Wu R., Xin H., Liu H., Lu T. Z., Zhao Y. C., Shen J. W., Hu Z. K., Yu P., Zhou L. H., Xu L. W., et al. (2015): Effects of ischemic preconditioning on the systemic and renal hemodynamic changes in renal ischemia reperfusion injury. *Int. J. Clin. Exp. Pathol.* **1**, 1128–1140
- Ghafourifar P., Schenk U., Klein S. D., Richter C. (1999): Mitochondrial nitric oxide stimulation causes cytochrome C release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation. *J. Biol. Chem.* **274**, 31185–31188  
<https://doi.org/10.1074/jbc.274.44.31185>
- Giulivi C., Poderoso J. J., Boveris A. (1998): Production of NO by mitochondria. *J. Biol. Chem.* **273**, 11038–11043  
<https://doi.org/10.1074/jbc.273.18.11038>
- Goligorsky M. S., Brodsky J. V., Noiri E. (2004): NO bioavailability, endothelial dysfunction, and acute renal failure: new insights in pathophysiology. *Semin. Nephrol.* **24**, 316–323  
<https://doi.org/10.1016/j.semnephrol.2004.04.003>
- Hausenloy D. J., Yellon D. M. (2009): Preconditioning and post-conditioning: underlying mechanisms and clinical application. *Atherosclerosis* **204**, 334–341  
<https://doi.org/10.1016/j.atherosclerosis.2008.10.029>
- Hickey M. J., Granger D. N., Kubes P. (2001): Inducible nitric oxide synthase (iNOS) and regulation of leucocyte/endothelial cell interactions: studies in iNOS-deficient mice. *Acta Physiol. (Scand)* **173**, 119–126  
<https://doi.org/10.1046/j.1365-201X.2001.00892.x>
- Ignarro L. J. (2000): Nitric Oxide: Biology and Pathophysiology. Academic press, San Diego
- Kosieradzki M., Rowinski W. (2008): Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. *Transplant. Proc.* **40**, 3279–3288  
<https://doi.org/10.1016/j.transproceed.2008.10.004>
- Kwon M. S., Kim M. H., Kim S. H., Park K. D., Yoo S. H., Oh I. U., Pak S., Seo Y. J. (2014): Erythropoietin exerts cell protective

- effect by activating PI3K/Akt and MAPK pathways in C6 Cells. *Neurol. Res.* **36**, 215–223  
<https://doi.org/10.1179/1743132813Y.0000000284>
- Kwon O., Hong S. M., Ramesh G. (2009): Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion. *Am. J. Physiol. Renal. Physiol.* **296**, F25–33  
<https://doi.org/10.1152/ajprenal.90531.2008>
- Laroux F. S., Pavlick K. P., Hines I. N., Kawachi S., Harada H., Bharwani S., Hoffman J. M., Grisham M. B. (2001): Role of nitric oxide in inflammation. *Acta Physiol. (Scand)* **173**, 113–118  
<https://doi.org/10.1046/j.1365-201X.2001.00891.x>
- Liu L., Liu C., Hou L., Lv J., Wu F., Yang X., Ren S., Ji W., Wang M., Chen L. (2015): Protection against ischemia/reperfusion-induced renal injury by cotreatment with erythropoietin and sodium selenite. *Mol. Med. Rep.* **12**, 7933–7940
- Li X. J., Zhang G. X., Sun N., Sun Y., Yang L. Z., Du Y. J. (2013): Protective effects of erythropoietin on endotoxin-related organ injury in rats. *J. Huazhong Univ. Sci. Technol. Med. Sci.* **33**, 680–686  
<https://doi.org/10.1007/s11596-013-1180-1>
- Lopez-Marti J., Sola A., Pi F., Alfaro V., Marco A., Hotter G. (2003): Nucleotides modulate renal ischemia-reperfusion injury by different effects on nitric oxide and superoxide. *Clin. Exp. Pharmacol. Physiol.* **30**, 242–248  
<https://doi.org/10.1046/j.1440-1681.2003.03821.x>
- Mastromarino V., Volpe M., Musumeci M. B., Autore C., Conti E. (2011): Erythropoietin and the heart: Facts and perspectives. *Clin. Sci. (Lond)* **120**, 51–63  
<https://doi.org/10.1042/CS201100305>
- Omer N., Rohilla A., Rohilla S., Kushnoor A. (2012): Nitric oxide: role in human biology. *Int. J. Pharm. Sci. Drug Res.* **4**, 105–109
- Park K. M., Byun J. Y., Kramers C. (2003): Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. *J. Biol. Chem.* **278**, 27256–27266  
<https://doi.org/10.1074/jbc.M301778200>
- Rezende-Neto J. B., Moore E. E., Melo de Andrade M. V., Teixeira M. M., Lisboa F. A., Arantes R. M., de Souza D. G., da Cunha-Melo J. R. (2002): Systemic inflammatory response secondary to abdominal compartment syndrome: Stage for multiple organ failure. *J. Trauma* **53**, 1121–1128  
<https://doi.org/10.1097/00005373-200212000-00015>
- Sheridan A. M., Bonventre J. V. (2001): Pathophysiology of ischemic acute renal failure. *Contrib. Nephrol.* **132**, 7–21  
<https://doi.org/10.1159/000060075>
- Shokeir A. A., Barakat N., Hussein A. M., Awadalla A., Harraz A. M., Khater S., Hemmaid K., Kamal A. I. (2015): Activation of Nrf2 by ischemic preconditioning and sulforaphane in renal ischemia/reperfusion injury: a comparative experimental study. *Physiol. Res.* **64**, 313–323
- Torras J., Herrero-Fresneda I., Lloberas N., Riera M., Ma Cruzado J., Ma Grinyó J. (2002): Promising effects of ischemic preconditioning in renal transplantation. *Kidney Int.* **61**, 2218–2227  
<https://doi.org/10.1046/j.1523-1755.2002.00360.x>
- Tsutsui H., Tanaka R., Yamagata M., Yukimura T., Ohkita M., Matsumura Y. (2013): Protective effect of ischemic preconditioning on ischemia/reperfusion-induced acute kidney injury through sympathetic nervous system in rats. *Eur. J. Pharmacol.* **718**, 206–212  
<https://doi.org/10.1016/j.ejphar.2013.08.032>
- Tymk K. (2011): Critical role for oxidative stress, platelets, and coagulation in capillary blood flow impairment in sepsis. *Microcirculation* **18**, 152–162  
<https://doi.org/10.1111/j.1549-8719.2010.00080.x>
- Vinas J. L., Sola A., Genseca M., Alfaro V., Pi F., Hotter G. (2006): NO and NOS isoforms in the development of apoptosis in renal ischemia/reperfusion. *Free Radic. Biol. Med.* **40**, 992–1003  
<https://doi.org/10.1016/j.freeradbiomed.2005.10.046>
- Wang H. B., Li Y. X., Hao Y. J., Wang T. F., Lei Z., Wu Y., Zhao Q. P., Anq H., Ma L., Liu J. et al. (2013): Neuroprotective effects of LBP on brain ischemic reperfusion neurodegeneration. *Eur. Rev. Med. Pharmacol. Sci.* **17**, 2760–2765
- Yao L., Lu P., Li Y., Yang L., Feng H., Huang Y., Zhang D., Chen J., Zhu D. (2013): Osthole relaxes pulmonary arteries through endothelial phosphatidylinositol 3-kinase/Akt-eNOS-NO signaling pathway in rats. *Eur. J. Pharmacol.* **699**, 23–32  
<https://doi.org/10.1016/j.ejphar.2012.11.056>
- Ysebaert D. K., De Greef K. E., Vercauteren S. R., Ghielli M., Verpooten G. A., Eyskens E. J., De Broe M. E. (2000): Identification and kinetics of leukocytes after severe ischemia/reperfusion renal injury. *Nephrol. Dial. Transplant.* **15**, 1562–1574  
<https://doi.org/10.1093/ndt/15.10.1562>
- Zhang J., Zou Y., Zhong X., Deng H. D., Pu L., Peng K., Wang L. (2015): Erythropoietin pretreatment ameliorates renal ischaemia-reperfusion injury by activating PI3K/Akt signalling. *Nephrology* **20**, 266–272  
<https://doi.org/10.1111/nep.12384>

Received: June 6, 2016

Final version accepted: July 28, 2016

First published online: May 4, 2017